Associate Director, In-Vivo Pharmacology

At Rayze Bio, every day is an opportunity to ignite meaningful change. As a wholly-owned subsidiary of Bristol Myers Squibb, Rayze Bio blends the nimble, pioneering spirit of an emergent biotech with the global expertise and resources of a leading innovator in oncology. Our mission is to develop transformative radiopharmaceutical therapies that offer new hope for patients living with cancer.

Here, you’ll join a multidisciplinary team where your ideas are valued, your expertise is amplified, and collaboration is at the heart of everything we do. From day one, expect to make an immediate impact—on our science, on our teams, and most importantly, on patients. Learn more about Rayze Bio:
Rayze Bio is seeking an Associate Director, In‑Vivo Pharmacology to provide scientific and operational leadership across oncology programs with a focus on radiopharmaceutical therapeutics (RPTs). This role provides functional leadership to senior scientists to design and execute high‑quality in‑vivo studies that inform program strategy from discovery through IND‑enabling development.

The Associate Director will set direction, ensure alignment, and drive high‑quality decision‑making, while maintaining accountability for vivarium operations, animal welfare, and regulatory compliance (IACUC/AALAC). This is a highly cross‑functional role that operates close to the science without serving as the primary experimentalist.  The ideal candidate combines deep expertise in oncology in‑vivo pharmacology with a strong sense of ownership, practical decision‑making, and comfort operating at the intersection of science, operations, and compliance in a fast‑moving biotech environment.

Key Responsibilities Lead the in‑vivo pharmacology strategy for oncology RPT programs by supporting scientists in study design, execution, data interpretation, and translational relevance.

Serve as a scientific thought partner, providing feedback and direction on: model selection (CDX/PDX), dose and schedule rationale and endpoint definition and evaluability.  Support selection of mouse strains, tumor models, activity levels, and fractionation schemes appropriate for Lu‑177, Ac‑225, and future RPT isotopes and modalities.

Ensure consistency, rigor, and strategic alignment across in‑vivo studies supporting multiple programs from early discovery through IND‑enabling development.

Own efficacy and biodistribution strategy for radiopharmaceutical programs, incorporating tumor growth kinetics, delayed response patterns, and modality‑specific considerations.  Ensure study designs reflect radiobiological realities.

Partner closely with dosimetry/physics, imaging, radiochemistry, biology and DMPK teams to align in‑vivo studies with absorbed dose and exposure‑response understanding.

Review and contribute to in‑vivo pharmacology sections of study reports and IND‑enabling regulatory submissions. Serve as a point of escalation for animal care, biosecurity, or facility‑related issues impacting studies and operations.

Education and Experience Ph.D. in Pharmacology, Cancer Biology, Toxicology, or related field, with 8+ years of relevant industry experience

Strong track record in in‑vivo oncology pharmacology, including xenograft efficacy studies and supporting preclinical programs advancing toward INDDemonstrated ability to lead complex, cross‑functional teams/efforts and make pragmatic decisions in a fast‑paced R&D environment

Working knowledge of IACUC processes, animal welfare regulations and experience supporting AALAC accreditation activities

Experience applying AI and computational tools to enhance data analysis, automate routine workflows, and support data-driven decision-making is desirable

Experience with radiopharmaceuticals, radioligand therapies, or…